Questioning Ionis Pharmaceuticals' Spinoff Announcement

Ionis Pharmaceuticals NASDAQ IONS is spinning off some of its lipid disorder drugs The new company Akcea will raise 100 million from its IPO and collaboration partner Novartis NYSE NVS will acquire an additional 50 million in shares concurrently While